top of page
Blog Posts
Search
Carl Kestens
2 days ago10 min read
The $10 billion unicorn in INmune Bio: on BioVie teachings and trustworthiness
Summary BioVie always argued that it saw a correlation between effects on cognition and reduction of TNF levels. That TNF reduction...
146 views
2 comments
Carl Kestens
Mar 615 min read
The $10 billion unicorn in INmune Bio: Leqembi and Kisunla’s MoA is microglia-related, and amyloid beta is a cytokine
Introduction Amyloid beta has been the primary hallmark of Alzheimer’s disease for years. On the one hand, numerous trials focusing on...
269 views
12 comments
Carl Kestens
Feb 2810 min read
The $10 billion unicorn in INmune Bio: where fraud and arrogance aren’t, solutions to AD are (C. Piller book coverage)
Introduction Science journalist Charles Piller wrote a book, called ‘Doctored: fraud, arrogance, and tragedy in the quest to cure...
308 views
1 comment
Carl Kestens
Feb 215 min read
The $10 billion unicorn in INmune Bio: XPro’s biomarkers outperform Leqembi's and Kisunla's
Introduction For years, the scientific focus may have been too focused on targeting amyloid, while inflammation and modulation of glial...
279 views
0 comments
Carl Kestens
Feb 1311 min read
The $10 billion unicorn in INmune Bio: inflammation drives cognitive decline
Summary INmune Bio is making significant strides across multiple programs, positioning itself as a major player in biotech. CORDstrom...
207 views
0 comments
Carl Kestens
Feb 711 min read
The $10 billion unicorn in INmune Bio: On Cassava Sciences and the Importance of a Bear Thesis for Proper Due Diligence
Summary Coverage of the Alzheimer’s space would be incomplete without a blog post on Cassava Sciences. Now was the right time. Cassava...
398 views
0 comments
Carl Kestens
Jan 3113 min read
The $10 billion unicorn in INmune Bio: Alzheimer’s, How Not To Study A Disease
On JLO, RFK, the NIH, TNF, Karl Herrup and innovation - a longer post. Â Summary The amyloid hypothesis did not yield the desired...
761 views
0 comments
Carl Kestens
Jan 249 min read
The $10 billion dollar unicorn in INmune Bio: is the FDA openly suggesting accelerated approval based on NfL?
Summary I had a call with some investors earlier this week. During the call, the theme of accelerated approval came up. I had done a blog...
496 views
0 comments
Carl Kestens
Jan 177 min read
The $10 billion unicorn in INmune Bio: how only INMB uses the recipe behind big pharma’s recent successes with anti-amyloid antibodies
Historical failure rate of therapies targeting amyloid Alzheimer’s is characterized by aggregation of anti-amyloid antibodies and...
669 views
0 comments
Carl Kestens
Jan 106 min read
The $10 billion dollar unicorn in INmune Bio: could remyelination explain the fast functional/cognitive recovery seen in patients?
Introduction I am picking up my previous work to assess the Alzheimer’s space today, with a particular focus on INmune Bio, as the...
980 views
0 comments
Carl Kestens
Oct 21, 202212 min read
The $10 billion dollar unicorn in INmune Bio: on fast-progressors in AD, APOE4, TREM2 and EMACC
Summary APOE4, involved in different mechanisms in the brain including lipid homeostasis, is the strongest risk factor for Alzheimer’s...
723 views
0 comments
Carl Kestens
Sep 23, 202212 min read
The $10 Billion unicorn in INmune Bio: the potential of XPro in Parkinson’s
Summary The evolution of the treatment failures for Parkinson’s disease has striking similarities with Alzheimer’s. Just like in...
622 views
0 comments
Carl Kestens
Sep 2, 20228 min read
The FDA’s two leaps at once: on fast approval pathways and neurofilament light
Summary Neurofilament Light (NfL) is potentially the most important biomarker in neurodegenerative diseases. The FDA’s AdCom validated...
632 views
0 comments
Carl Kestens
Jul 30, 20229 min read
The $10 billion unicorn in INMB: on allostatic load, and why all the others may have non-responders
Summary Allostatic load is the cumulative burden of stressors one encounters throughout life. The underlying causes/triggers for any...
750 views
1 comment
Carl Kestens
Jun 9, 20229 min read
THE INFLAMED MIND, A Radical New Approach to Depression, by Ed Bullmore
A book review with some notes on my recent research, part I Introduction I have stated before that I believe that the field of psychiatry...
135 views
0 comments
Carl Kestens
May 7, 202213 min read
XPRO FOR THE DEPRESSED MIND, PART 1: INMB’S MOST IGNORED POTENTIAL
Introduction For some time now, INmune Bio has been announcing their trial in treatment resistant depression (TRD). The market, either...
345 views
4 comments
Carl Kestens
Apr 23, 202210 min read
THE $10 BILLION UNICORN IN INMUNE BIO: IT’S THE (MICRO)GLIA, STUPID!
Summary: · The detrimental action of glia, mostly microglia, in the inflamed brain is the last piece of the scientific puzzle; · ...
658 views
7 comments
Carl Kestens
Apr 17, 20226 min read
Medicare coverage refused for Aduhelm and amyloid-based therapies: what’s next?
The 7 April 2022 CMS decision denying Aduhelm medicare coverage On 7 April 2022, the Centers for Medicare and Medicaid Services (CMS)...
145 views
0 comments
Carl Kestens
Apr 8, 20227 min read
WHY IT IS SENSIBLE TO ADDRESS SUB-COHORTS IN ALZHEIMER’S DISEASE
"I think a good drug might fail in a clinical trial because not all the subjects have the same kind of Alzheimer's. Shubhabrata...
395 views
1 comment
Carl Kestens
Mar 18, 202223 min read
CJ Barnum spoke, I listened
Introduction CJ Barnum, head of neuroscience at INMB, has a talent for translating his superior scientific knowledge to a crowd. The...
409 views
1 comment
bottom of page